AMNEAL EU LTD
PharmaAMNEAL EU LTD is a pharmaceutical company focused on Cardiovascular, Metabolic.
AMNEAL EU LTD at a Glance
- Strong track record with 85% execution quality across 11 trials
- Fast trial execution (8 months median completion)
AMNEAL EU LTD's Key Drugs
AMNEAL EU LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
AMNEAL EU LTD's Recent FDA Approvals
AMNEAL EU LTD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
AMNEAL EU LTD's Therapeutic Areas
AMNEAL EU LTD's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AMNEAL EU LTD's Top Competitors
AMNEAL EU LTD's closest competitors by therapeutic-area and drug-target overlap include Merck, Sanofi, and AstraZeneca. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AMNEAL EU LTD Pipeline Snapshot
Active clinical trials for AMNEAL EU LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 6/7 completed
- • Speed: 8 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2026-07-09
- Latest
- 2026-07-09
- Applications
- 3
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges